Estrella Immunopharma, Inc. (NASDAQ:ESLA) Shares Shorted: Short Interest Up 180.2% in October

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 599,647 shares, a growth of 180.2% from the September 30th total of 214,030 shares. Based on an average daily volume of 7,569,648 shares, the short-interest ratio is presently 0.1 days. Currently, 1.5% of the company’s stock are sold short.

Estrella Immunopharma Price Performance

NASDAQ:ESLA traded down $0.09 during mid-day trading on Friday, reaching $0.64. The stock had a trading volume of 165,669 shares, compared to its average volume of 625,500. Estrella Immunopharma has a fifty-two week low of $0.24 and a fifty-two week high of $3.15. The stock has a market cap of $27.81 million, a P/E ratio of -2.66 and a beta of 0.93. The business’s 50 day moving average is $0.58 and its 200 day moving average is $0.98.

Estrella Immunopharma (NASDAQ:ESLA) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.04. Equities analysts expect that Estrella Immunopharma will post -0.25 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Hedge Funds Weigh In On Estrella Immunopharma

An institutional investor recently bought a new stake in Estrella Immunopharma stock. BlackRock Inc. purchased a new stake in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 52,033 shares of the company’s stock, valued at approximately $54,000. BlackRock Inc. owned 0.12% of Estrella Immunopharma as of its most recent filing with the Securities & Exchange Commission. 0.35% of the stock is owned by institutional investors and hedge funds.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc (NASDAQ: ESLA) is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and other serious diseases. The company’s work centers on genetically engineered T-cell therapies designed to recognize and destroy target cells.

Estrella’s lead program is EB103, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy being developed for the treatment of certain B-cell malignancies. The company has described EB103 as being based on its ARTEMIS platform, which is intended to support targeted immune-cell activity while addressing some limitations associated with conventional CAR-T therapies.

Estrella became a publicly traded company through a business combination with TradeUP Global Corporation.